Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression

Figure 3

TAS106 suppressed DNA repair capacity in A549 cells. (A) Survival ratio of A549 cells after fractionated irradiation. Cells were pretreated with TAS106 (1 μM) for 24 h and then irradiated (2.5 Gy). After incubation for the indicated times, they were irradiated (2.5 Gy) again and cultured for colony formation. The survival ratios were normalized to unity at time 0 h for each group. Data are expressed as mean ± SE of three experiments. *p < 0.05, significant difference by the Mann-Whitney U test. (B) γ-H2AX and (C) 53BP1 focus formation after X-irradiation. Cells were pretreated with TAS106 (1 μM) for 24 h, followed by X-irradiation (1 Gy). They were then fixed at the indicated times to evaluate the nuclear γ-H2AX focus formation. The numbers of foci in at least 20 cells were scored and the average numbers were plotted in the graph. Data are expressed as mean ± SE of three experiments. *p < 0.05, significant difference by Student's t-test.

Back to article page

Molecular Cancer

ISSN: 1476-4598